- Specialty Pharmacy List
- CAP Patient Enrollment Form
- Altera® Nebulizer System Instructions for Use
- Altera® Nebulizer System Instructions for Use en Español
CAYSTON's safety profile was clinically evaluated in multiple studies
The safety profile of CAYSTON was evaluated in 344 patients from 2 placebo-controlled trials (AIR-CF1 and AIR-CF2) and 1 open-label follow-on trial (AIR-CF3).
Adverse reactions reported in ≥5% of patients treated with CAYSTON in the placebo-controlled trials
Adverse reactions that occurred in <5% of patients treated with CAYSTON were bronchospasm (3%) and rash (2%).
Low incidence of altered taste: In AIR-CF1, dysgeusia (altered taste) was reported by 1 patient treated with 75 mg CAYSTON and 1 placebo-treated patient.4